Skip to main content

This enables patients in all countries where Pharming’s product RUCONEST® is not commercially available to gain access to the drug through an ethical and regulatory compliant mechanism. It is the only known program of this type which has been initiated through a patient group.

“HAEi exists to support patients with HAE gain access to HAE therapies to improve their quality of life and potentially be life-saving in the case of a laryngeal attack,”

- Henrik Balle Boysen, HAEi Executive Director
Cookies: This website uses cookies Check the cookies page for more information Accept Decline